< 1 minute read
Nov. 26, 2021

LYC-55716: An Oral RORγ Nuclear Receptor Agonist


oral RORγ nuclear receptor agonist 450 mg BID, phase I/II, cancer from change in MoA of RORγ antagonist + opt. Journal of Medicinal Chemistry Lycera

Drug Hunter Team

The Lycera ROR gamma agonist, cintirorgon ( LYC-55716 ), is a first-in-class phase 1b clinical candidate for cancer immunotherapy (in combination with pembrolizumab in NSCLC). ROR gamma antagonists have been extensively pursued and studied for autoimmune conditions, but ROR gamma agonists have also been recently pursued for “pro-inflammatory” [...]



Other molecules you may be interested in